Autres langues

09/07 Afternoon Meeting: Wall Street ignora las alarmas
09/07 Wall Street Ignores the Sirens
09/07 GSK adds Royal Philips' Chief Executive Jakobs to board
09/07 Öl hält die Märkte in Atem
09/07 Oil keeps markets on edge
09/07 UK Stocks-Factors to watch on July 9
08/07 Alector and GSK partnership to end after dementia, Alzheimer's drug failures
08/07 Alector, Inc. Announces Termination of Collaboration Agreement with Glaxo Wellcome UK Limited
08/07 Alector LLC and Alector, Inc. Repay $10,428,827.77 Aggregate Principal Amount Of Loans Under Loan And Security Agreement With Hercules Capital, Inc
08/05 Alector : Quarterly Report for Quarter Ending March 31, 2026 (Form 10-Q)
07/05 Alector: Q1 Earnings Snapshot
07/05 Alector, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026
07/05 Alector Reports First Quarter 2026 Financial Results and Provides Business Update
29/04 Alector to discontinue phase 2 trial of nivisnebart
29/04 Alector to Discontinue Phase 2 PROGRESS-AD Trial of Nivisnebart (AL101/GSK4527226) in Early Alzheimer’s Disease Following Interim Futility Analysis
29/04 Alector Inc Discontinues Phase 2 Progress-Ad Trial of Nivisnebart and Provides Pipeline Update
15/04 Alector Shares Rise After Cantor Fitzgerald Upgrade
25/03 Alector : March 2026 Corporate Presentation
12/03 Alector Files $400 Million Mixed Shelf
10/03 Alector Shares Rise After BTIG Upgrade
25/02 Alector : February 2026 Corporate Presentation
25/02 Alector: Q4 Earnings Snapshot
25/02 Alector, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025
25/02 Alector Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
24/02 Alector to Participate in the TD Cowen 46th Annual Health Care Conference
Aucun résultat pour cette recherche